Guideline-Based Medication Regimen for Heart Failure with Reduced Ejection Fraction
All adults with HFrEF should receive quadruple therapy consisting of an SGLT2 inhibitor, an ARNI (or ACE inhibitor if ARNI not tolerated), a beta-blocker, and a mineralocorticoid receptor antagonist—these four medication classes form the foundational treatment that reduces both hospitalization and mortality. 1
The Four Pillars of HFrEF Treatment
The 2022 AHA/ACC/HFSA guidelines establish that guideline-directed medical therapy (GDMT) now includes four mandatory medication classes 1:
1. SGLT2 Inhibitors (First-Line Therapy)
- Dapagliflozin 10 mg daily OR Empagliflozin 10 mg daily 1, 2
- Start immediately at diagnosis—benefits emerge within weeks 3
- No titration needed; use target dose from day one
- Use regardless of diabetes status 4
2. ARNI or ACE Inhibitor (RAS Inhibition)
- Preferred: Sacubitril-valsartan starting 24/26 mg or 49/51 mg twice daily, target 97/103 mg twice daily 1, 2
- Alternative if ARNI not tolerated: ACE inhibitor (enalapril 2.5 mg twice daily, target 10-20 mg twice daily) 2
- ARNI is superior to ACE inhibitors and should replace them in symptomatic patients 5
- Never combine ACE inhibitor with ARB and MRA due to hyperkalemia and renal dysfunction risk 5
3. Evidence-Based Beta-Blockers
Choose one of three proven agents 2:
- Carvedilol 3.125 mg twice daily, target 25-50 mg twice daily
- Metoprolol succinate 12.5-25 mg daily, target 200 mg daily
- Bisoprolol 1.25 mg daily, target 10 mg daily
- Start alongside ARNI/ACE inhibitor, not sequentially 1
4. Mineralocorticoid Receptor Antagonists
- Spironolactone 12.5-25 mg daily, target 25-50 mg daily OR
- Eplerenone 25 mg daily, target 50 mg daily 1, 2
- Add for patients symptomatic despite ARNI and beta-blocker 5
- Monitor potassium and renal function closely
Implementation Strategy: "Four Drugs in 4 Weeks"
Initiate all four medication classes rapidly—within the first month of diagnosis—rather than waiting months between additions 3. The evidence shows:
- Start SGLT2 inhibitor and beta-blocker immediately at diagnosis
- Add ARNI (or ACE inhibitor) within the first week
- Add MRA within 2-4 weeks if symptomatic
- Uptitrate to target doses within 6-12 weeks 6
This aggressive approach is supported by the 2022 guidelines, which emphasize that clinical trials used forced-titration strategies to reach target doses regardless of symptom improvement at lower doses 2. The mortality benefit comes from achieving target doses, not just "some dose."
Critical Dosing Principle
Target doses from clinical trials are what reduce mortality—not lower doses 7, 2. The number needed to treat (NNT) to prevent one death over 36 months is:
- Beta-blockers: NNT = 9
- MRA: NNT = 6
- ARNI: NNT = 27
- SGLT2i: NNT = 22 2
These benefits only apply when medications are titrated to target doses using the forced-titration strategies from landmark trials 7.
Additional Therapies for Specific Situations
If Congestion Present:
- Loop diuretics (furosemide, torsemide) to relieve symptoms 5
- Titrate to euvolemia, not a fixed dose
If Still Symptomatic on Quadruple Therapy:
Consider adding:
- Vericiguat 2.5 mg daily, target 10 mg daily (for recent decompensation) 2
- Hydralazine-isosorbide dinitrate 37.5/20 mg three times daily, target 75/40 mg three times daily (particularly for African American patients) 2
- Ivabradine 5 mg twice daily if heart rate >70 bpm on maximally tolerated beta-blocker 2
If Atrial Fibrillation Present:
- Continue all four pillars
- Add anticoagulation
- Consider digoxin for rate control if needed 2
Common Pitfalls to Avoid
Do not delay initiation waiting for "stability"—start all four classes early unless absolute contraindications exist 3. Real-world data shows persistent underutilization stems from delayed initiation and fear of side effects 8.
Do not stop uptitration when symptoms improve—continue to target doses as used in clinical trials 7, 2.
Do not use non-evidence-based beta-blockers (metoprolol tartrate, atenolol)—only carvedilol, metoprolol succinate, or bisoprolol reduce mortality 2.
Avoid calcium channel blockers (diltiazem, verapamil)—they worsen heart failure and increase hospitalizations 5.
Managing Common Barriers
Hypotension:
- Separate timing of medications throughout the day
- Reduce/stop non-essential antihypertensives
- Accept systolic BP 90-100 mmHg if asymptomatic 9
Hyperkalemia:
- Optimize diuretics first
- Consider potassium binders (patiromer, sodium zirconium cyclosilicate)
- Do not reflexively stop MRA—adjust other medications first 9
Worsening Renal Function:
- Accept 20-30% creatinine increase if stable thereafter
- Continue SGLT2i even with eGFR decline
- Adjust doses, don't discontinue 9
Device Therapy Considerations
After 3 months of optimal medical therapy, evaluate for:
- ICD if LVEF ≤35% and NYHA class II-III (primary prevention) 5
- CRT if LVEF ≤35%, QRS ≥150 msec with LBBB morphology 5
The medication regimen must be optimized first—devices are adjunctive, not substitutes for pharmacotherapy 1.